Skip to main content

Table 2 Patients’ characteristics with sarcopenia (n = 19) and non-sarcopenia (n = 36)

From: Recovery of physical function in lung transplant recipients with sarcopenia

 

Total (n = 55)

Sarcopenia (n = 19)

Non-sarcopenia (n = 36)

P-value

Patients' characteristics

    

 Age at LTX, median (IQR)

44 (33–50)

45 (34–50)

44 (33–50)

0.878

 Female, n (%)

29 (52.7%)

12 (63.2%)

17 (47.2%)

0.260

 LTX procedure, n (%)

   

0.529

  Single

27 (49.1%)

8 (42.1%)

19 (52.8%)

 

  Double

27 (49.1%)

11 (57.9%)

17 (47.2%)

 

  Living-donor

1 (1.8%)

1 (5.3%)

0 (0.0%)

 

 LTX indication, n (%)

   

0.550

  Pulmonary Vascular Disease

10 (18.2%)

5 (26.3%)

5 (13.9%)

 

  Restrictive Lung Disease

14 (25.5%)

4 (21.1%)

10 (27.8%)

 

  Obstructive Lung Disease

20 (36.4%)

8 (42.1%)

12 (33.3%)

 

  Suppurative Lung Disease

8 (14.5%)

1 (5.3%)

7 (19.4%)

 

  Others

3 (5.4%)

1 (5.3%)

2 (5.6%)

 

Pre- and intra-operative condition

    

 6MWD (m), median (IQR)

318 (216–373)

316 (221–387)

318 (204–369)

0.524

 Body-mass index (kg/m2), median (IQR)

18.0 (17.0–22.0)

18.0 (17.0–24.0)

18.5 (16.3–21.0)

0.815

 On supplemental oxygen, n (%)

49 (89.1%)

17 (89.5%)

32 (88.9%)

0.999

 Diabetes, n (%)

4 (7.3%)

3 (15.8%)

1 (2.8%)

0.077

 Connective tissue disease, n (%)

9 (16.4%)

3 (15.8%)

6 (16.7%)

0.933

 Chronic kidney disease, n (%)

2 (3.6%)

2 (10.5%)

0 (0.0%)

0.047

 Waiting time (month), median (IQR)

26 (18–36)

26 (19–37)

26 (17–35)

0.559

 Donor age, median (IQR)

43 (31–47)

43 (26–49)

42.5 (31.5–51)

0.411

 Ischemic time (min)

535 (452–697)

483 (403–717)

555 (456–694)

0.323

 CMV mismatch (D + /R-), n (%)

10 (18.2%)

5 (26.3%)

5 (13.9%)

0.288

Post-operative condition and complications

    

 Primary graft dysfunction, n (%)

45 (81.8%)

17 (89.5%)

28 (77.8%)

0.465

 Requirement of tracheostomy, n (%)

28 (50.9%)

13 (68.4%)

15 (42.7%)

0.089

 Continuous renal replacement therapy, n (%)

9 (16.4%)

5 (26.3%)

4 (11.1%)

0.249

 Invasive mechanical ventilation (day), median (IQR)

12 (4–29)

18 (5–60)

7 (4–21)

0.052

 ICU stay (day), median (IQR)

19 (9–39)

29 (16–68)

15 (7–31)

0.024

 Hospital stay (day), median (IQR)

85 (64–114)

98 (64–170)

81 (62–95)

0.060

 Acute allograft rejection, n (%)

9 (16.4%)

3 (15.8%)

6 (16.7%)

0.999

 ESM-CSA ( cm2/m2), median (IQR)

15.7 (14.0–17.9)

13.6 (12.6–14.9)

17.3 (14.8–18.8)

 < .0001

 %predicted hand-grip strength, median (IQR)

54.0 (43.5–62.0)

39.0 (28.0–49.0)

58.0 (52.0–67.0)

 < .0001

 Hand-grip strength (kg), median (IQR)

20.0 (15.0–28.0)

14.0 (11.8–17.3)

24.0 (20.0–29.0)

 < .0001

 %predicted 6MWD, median (IQR)

65.0 (48.0–79.0)

39.0 (31.0–64.0)

74.5 (62.0–81.8)

 < .0001

 6MWD (m), median (IQR)

447 (309–483)

309 (195–399)

476 (426–519)

 < .0001

 Body-mass index (kg/m2), median (IQR)

17.0 (15.0–21.0)

17.0 (15.0–22.0)

17.0 (16.0–20.0)

0.891

 FEV1 (L), median (IQR)

1.56 (1.30–1.95)

1.36 (1.13–1.56)

1.78 (1.37–2.02)

0.013

 Follow-up duration in months, median (IQR)

48 (26–70)

43 (22–76)

49 (27–67)

0.571

  1. Bold values of p < 0.05 were considered statistically significant
  2. LTX, lung transplant; IQR, interquartile range; 6MWD, 6-min walk distance; CMV, cytomegalovirus; D, donor; R; recipient, ICU, intensive care unit; FEV1, forced expiratory volume in one second